The government of Russia’s capital Moscow has announced a record tender for the current year, which involves the establishment of production and further supplies of drugs on the total sum of 22.6 billion roubles ($342 million) by 2028, reports The Pharma Letter’s local correspondent.
Under the terms of the tender, the winner will have to establish the production of at least 31 drugs from the approved list by investing at least 3 billion roubles in their production. Deliveries need to have been completed by2028.
In the meantime, the conditions of the tender have already been criticized by some leading Russian drugmakers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze